Resistance of HIV to antiretroviral drugs is the most common cause of therapeutic failure in patients infected with HIV. Detection and reporting of drug resistance mutations (DRMs) is critical for optimal selection of Highly Active Antiretroviral Therapy (HAART) regimen and can prevent or minimize the development of resistance to antiviral drugs.
Using next generation sequencing (NGS) technology, the Sentosa® SQ HIV-1 Genotyping Assay developed by Vela Diagnostics detects DRMs with high sensitivity and reproducibility in 3 major antiretroviral drug targeted regions of the Pol gene – Protease (PR), Reverse Transcriptase (RT) and Integrase (IN), in HIV-1 Group M strains. The assay is performed on the automated VELA NGS Workflow, which has one of the shortest turnaround time and hands-on time available in the market for HIV-1 genotyping.
The Sentosa® SQ HIV-1 Genotyping Assay has been granted marketing authorization by the US FDA and HSA (Singapore), and an earlier version has also been CE-IVD, TGA, Thai FDA approved. Read the press releases on the FDA and Vela Diagnostics websites.